Researchers at UT Southwestern Medical Center have found.

Related StoriesBrain cells in Parkinson's prematurely disease die, burning out as an overheating motorTSRI scientists awarded grant to explore therapeutic potential of proteins receptors in Parkinson's disease, other disordersSynAgile announces excellent results from Phase 2a trial of continuous intraoral LD/CD therapyParticipants with and without hyposmia were similar when it comes to age, gender, smoking family members and status background of PD.Using the insights from the trial and input from regulators in European countries and the US, Cardio3 BioSciences is currently designing a pivotal scientific trial program for C-Cure likely to begin in 2011. With the Phase II stage completed and to allow for potential adjustments to the trial protocol, Cardio3 BioSciences will not continue recruitment in to the existing trial but will continue to collect all data for the six month evaluation.. CFDA accepts WuXi MedImmune’s novel anti-IL6 monoclonal antibody IND application for review WuXi PharmaTech Inc. , a leading open-access R&D capability and technology platform business serving the global pharmaceutical, biotechnology, and medical device industries, announced today an Investigational New Medication program for WuXi MedImmune's novel anti-IL6 monoclonal antibody for arthritis rheumatoid has been accepted for review by the China Food and Drug Administration .

Comments are closed.